Review



polyclonal goat anti human tarc antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems polyclonal goat anti human tarc antibody
    Figure 1. A–C, cHL with multiple HRS cells that are CD30-positive (B). <t>TARC</t> IHC in this case shows strong cytoplasmic staining in all the tumour cells (C). D–F, EBV-positive cHL with HRS cells that show diffuse CD30 positivity (E). TARC IHC shows a weak and incomplete stain- ing pattern (F). G–I, Nodular lymphocyte predominant Hodgkin lymphoma with CD20-positive tumour cells (H). TARC IHC in this case is completely negative in all tumour cells (I). cHL, classic Hodgkin lymphoma; HRS, Hodgkin/Reed–Sternberg; IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.
    Polyclonal Goat Anti Human Tarc Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti human tarc antibody/product/R&D Systems
    Average 94 stars, based on 6 article reviews
    polyclonal goat anti human tarc antibody - by Bioz Stars, 2026-06
    94/100 stars

    Images

    1) Product Images from "The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics."

    Article Title: The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics.

    Journal: Histopathology

    doi: 10.1111/his.14836

    Figure 1. A–C, cHL with multiple HRS cells that are CD30-positive (B). TARC IHC in this case shows strong cytoplasmic staining in all the tumour cells (C). D–F, EBV-positive cHL with HRS cells that show diffuse CD30 positivity (E). TARC IHC shows a weak and incomplete stain- ing pattern (F). G–I, Nodular lymphocyte predominant Hodgkin lymphoma with CD20-positive tumour cells (H). TARC IHC in this case is completely negative in all tumour cells (I). cHL, classic Hodgkin lymphoma; HRS, Hodgkin/Reed–Sternberg; IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.
    Figure Legend Snippet: Figure 1. A–C, cHL with multiple HRS cells that are CD30-positive (B). TARC IHC in this case shows strong cytoplasmic staining in all the tumour cells (C). D–F, EBV-positive cHL with HRS cells that show diffuse CD30 positivity (E). TARC IHC shows a weak and incomplete stain- ing pattern (F). G–I, Nodular lymphocyte predominant Hodgkin lymphoma with CD20-positive tumour cells (H). TARC IHC in this case is completely negative in all tumour cells (I). cHL, classic Hodgkin lymphoma; HRS, Hodgkin/Reed–Sternberg; IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.

    Techniques Used: Staining, Immunohistochemistry, Activation Assay

    Figure 2. A, B, reactive lymphadenopathy with multiple CD30-positive immunoblastic cells. TARC proved to be completely negative (B). C, D, Follicular lymphoma with numerous CD30-positive large B cell blasts (C). TARC IHC shows variable staining in part of the blasts (D). E, F, B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and classic Hodgkin lymphoma. TARC IHC is weakly positive in part of the tumour cells; the remainder is negative (F). G, H, primary mediastinal B cell lymphoma. TARC IHC shows a weak/variable staining with clear negativity of part of the tumour cells (H). IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.
    Figure Legend Snippet: Figure 2. A, B, reactive lymphadenopathy with multiple CD30-positive immunoblastic cells. TARC proved to be completely negative (B). C, D, Follicular lymphoma with numerous CD30-positive large B cell blasts (C). TARC IHC shows variable staining in part of the blasts (D). E, F, B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and classic Hodgkin lymphoma. TARC IHC is weakly positive in part of the tumour cells; the remainder is negative (F). G, H, primary mediastinal B cell lymphoma. TARC IHC shows a weak/variable staining with clear negativity of part of the tumour cells (H). IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.

    Techniques Used: Staining, Immunohistochemistry, Activation Assay



    Similar Products

    human ccl17/tarc biotinylated antibody  (Bio-Techne corporation)
    90
    Bio-Techne corporation human ccl17/tarc biotinylated antibody
    Human Ccl17/Tarc Biotinylated Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human ccl17/tarc biotinylated antibody/product/Bio-Techne corporation
    Average 90 stars, based on 1 article reviews
    human ccl17/tarc biotinylated antibody - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    polyclonal goat anti human tarc antibody  (R&D Systems)
    94
    R&D Systems polyclonal goat anti human tarc antibody
    Figure 1. A–C, cHL with multiple HRS cells that are CD30-positive (B). <t>TARC</t> IHC in this case shows strong cytoplasmic staining in all the tumour cells (C). D–F, EBV-positive cHL with HRS cells that show diffuse CD30 positivity (E). TARC IHC shows a weak and incomplete stain- ing pattern (F). G–I, Nodular lymphocyte predominant Hodgkin lymphoma with CD20-positive tumour cells (H). TARC IHC in this case is completely negative in all tumour cells (I). cHL, classic Hodgkin lymphoma; HRS, Hodgkin/Reed–Sternberg; IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.
    Polyclonal Goat Anti Human Tarc Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti human tarc antibody/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    polyclonal goat anti human tarc antibody - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    goat polyclonal anti human tarc ccl17  (R&D Systems)
    93
    R&D Systems goat polyclonal anti human tarc ccl17
    Figure 1. A–C, cHL with multiple HRS cells that are CD30-positive (B). <t>TARC</t> IHC in this case shows strong cytoplasmic staining in all the tumour cells (C). D–F, EBV-positive cHL with HRS cells that show diffuse CD30 positivity (E). TARC IHC shows a weak and incomplete stain- ing pattern (F). G–I, Nodular lymphocyte predominant Hodgkin lymphoma with CD20-positive tumour cells (H). TARC IHC in this case is completely negative in all tumour cells (I). cHL, classic Hodgkin lymphoma; HRS, Hodgkin/Reed–Sternberg; IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.
    Goat Polyclonal Anti Human Tarc Ccl17, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat polyclonal anti human tarc ccl17/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    goat polyclonal anti human tarc ccl17 - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    biotinylated goat anti human tarc polyclonal  (R&D Systems)
    90
    R&D Systems biotinylated goat anti human tarc polyclonal
    Fig. 1 Different types of immunoelectrophoresis of cat hair extract (Fel d) using a <t>polyclonal</t> rabbit antibody raised against the same extract (a Fel d). (a) CIE of Fel d extract, (b) FRIE following a purification (immunoab- sorption) of the major allergen Fel d 1, (c) CIE of purified Fel d 1 against a Fel d, (d) CLIE with Fel d 1 in inter- mediate gel for identification of the allergen, (e) TCIE with Fel d extract and Fel d 1 showing a double peak, (f) CIIE with monospecific Fel d 1 in intermediate gel
    Biotinylated Goat Anti Human Tarc Polyclonal, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/biotinylated goat anti human tarc polyclonal/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    biotinylated goat anti human tarc polyclonal - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    polyclonal goat-anti-human tarc antibody  (R&D Systems)
    90
    R&D Systems polyclonal goat-anti-human tarc antibody
    Fig. 1 Different types of immunoelectrophoresis of cat hair extract (Fel d) using a <t>polyclonal</t> rabbit antibody raised against the same extract (a Fel d). (a) CIE of Fel d extract, (b) FRIE following a purification (immunoab- sorption) of the major allergen Fel d 1, (c) CIE of purified Fel d 1 against a Fel d, (d) CLIE with Fel d 1 in inter- mediate gel for identification of the allergen, (e) TCIE with Fel d extract and Fel d 1 showing a double peak, (f) CIIE with monospecific Fel d 1 in intermediate gel
    Polyclonal Goat Anti Human Tarc Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat-anti-human tarc antibody/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    polyclonal goat-anti-human tarc antibody - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. A–C, cHL with multiple HRS cells that are CD30-positive (B). TARC IHC in this case shows strong cytoplasmic staining in all the tumour cells (C). D–F, EBV-positive cHL with HRS cells that show diffuse CD30 positivity (E). TARC IHC shows a weak and incomplete stain- ing pattern (F). G–I, Nodular lymphocyte predominant Hodgkin lymphoma with CD20-positive tumour cells (H). TARC IHC in this case is completely negative in all tumour cells (I). cHL, classic Hodgkin lymphoma; HRS, Hodgkin/Reed–Sternberg; IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.

    Journal: Histopathology

    Article Title: The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics.

    doi: 10.1111/his.14836

    Figure Lengend Snippet: Figure 1. A–C, cHL with multiple HRS cells that are CD30-positive (B). TARC IHC in this case shows strong cytoplasmic staining in all the tumour cells (C). D–F, EBV-positive cHL with HRS cells that show diffuse CD30 positivity (E). TARC IHC shows a weak and incomplete stain- ing pattern (F). G–I, Nodular lymphocyte predominant Hodgkin lymphoma with CD20-positive tumour cells (H). TARC IHC in this case is completely negative in all tumour cells (I). cHL, classic Hodgkin lymphoma; HRS, Hodgkin/Reed–Sternberg; IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.

    Article Snippet: T A R C I M M U N O H I S T O C H E M I S T R Y Paraffin tissue sections (3 lm) were incubated with polyclonal goat anti-human TARC antibody (1:800; R&D Systems, Minneapolis, MN, USA) on the automated Benchmark ULTRA platform (Ultra CC1, 52 min; Roche, Ventana Medical Systems, Oro Valley, AZ, USA).

    Techniques: Staining, Immunohistochemistry, Activation Assay

    Figure 2. A, B, reactive lymphadenopathy with multiple CD30-positive immunoblastic cells. TARC proved to be completely negative (B). C, D, Follicular lymphoma with numerous CD30-positive large B cell blasts (C). TARC IHC shows variable staining in part of the blasts (D). E, F, B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and classic Hodgkin lymphoma. TARC IHC is weakly positive in part of the tumour cells; the remainder is negative (F). G, H, primary mediastinal B cell lymphoma. TARC IHC shows a weak/variable staining with clear negativity of part of the tumour cells (H). IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.

    Journal: Histopathology

    Article Title: The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics.

    doi: 10.1111/his.14836

    Figure Lengend Snippet: Figure 2. A, B, reactive lymphadenopathy with multiple CD30-positive immunoblastic cells. TARC proved to be completely negative (B). C, D, Follicular lymphoma with numerous CD30-positive large B cell blasts (C). TARC IHC shows variable staining in part of the blasts (D). E, F, B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and classic Hodgkin lymphoma. TARC IHC is weakly positive in part of the tumour cells; the remainder is negative (F). G, H, primary mediastinal B cell lymphoma. TARC IHC shows a weak/variable staining with clear negativity of part of the tumour cells (H). IHC, immunohistochemistry; TARC, thymus and activation-related chemokine.

    Article Snippet: T A R C I M M U N O H I S T O C H E M I S T R Y Paraffin tissue sections (3 lm) were incubated with polyclonal goat anti-human TARC antibody (1:800; R&D Systems, Minneapolis, MN, USA) on the automated Benchmark ULTRA platform (Ultra CC1, 52 min; Roche, Ventana Medical Systems, Oro Valley, AZ, USA).

    Techniques: Staining, Immunohistochemistry, Activation Assay

    Fig. 1 Different types of immunoelectrophoresis of cat hair extract (Fel d) using a polyclonal rabbit antibody raised against the same extract (a Fel d). (a) CIE of Fel d extract, (b) FRIE following a purification (immunoab- sorption) of the major allergen Fel d 1, (c) CIE of purified Fel d 1 against a Fel d, (d) CLIE with Fel d 1 in inter- mediate gel for identification of the allergen, (e) TCIE with Fel d extract and Fel d 1 showing a double peak, (f) CIIE with monospecific Fel d 1 in intermediate gel

    Journal: Methods in Molecular Biology

    Article Title: Allergy

    doi: 10.1007/978-1-4939-9591-2

    Figure Lengend Snippet: Fig. 1 Different types of immunoelectrophoresis of cat hair extract (Fel d) using a polyclonal rabbit antibody raised against the same extract (a Fel d). (a) CIE of Fel d extract, (b) FRIE following a purification (immunoab- sorption) of the major allergen Fel d 1, (c) CIE of purified Fel d 1 against a Fel d, (d) CLIE with Fel d 1 in inter- mediate gel for identification of the allergen, (e) TCIE with Fel d extract and Fel d 1 showing a double peak, (f) CIIE with monospecific Fel d 1 in intermediate gel

    Article Snippet: Detection: Biotinylated goat anti-human TARC polyclonal (R&D Systems #BAF364 or PeproTech).

    Techniques: Immunoelectrophoresis, Purification